[6] Until large, prospective trials will demonstrate an advantage to treat earlier patients with asymptomatic CLL and high-risk ... remains a reasonable treatment option for elderly patients ...

Data are now accumulating on the feasibility of various treatment options even in unfit patients and there is an increased awareness that the chronological age by itself sometimes does not reflect ...

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on ...

and symptoms that indicate a more active disease pattern guide treatment initiation for CLL. The International Workshop on CLL has published guidelines. At least one of the following must be ...

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14 ...

If your CLL is in the early stages, you may not need treatment right away. If you do, your treatment will depend on your cancer stage, symptoms, total health, and preferences. Treatment options ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

Given their ability to inhibit STAT3 activation, we hypothesized that concomitant treatment with phorbol esters would enhance the immunogenic properties of S28690-treated CLL cells. Consistent ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Both AZ and BeiGene are hoping to dislodge Imbruvica by running head-to-head trials of their new drugs against the market leader, focusing on second-line treatment of previously-treated CLL.